[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cholangitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cholangitis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,73,102,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":44,"locationsCount":47},"100643432","sedation-methods-in-percutaneous-transhepatic-biliary-drainage-procedure-quality-and-recovery-100643432",false,"NCT07640243","Sedation Methods in Percutaneous Transhepatic Biliary Drainage: Procedure Quality and Recovery","Evaluation of Sedation Methods Used in Percutaneous Transhepatic Biliary Drainage Procedures in Terms of Procedure Quality, Recovery Time, and Side Effects","Inclusion Criteria:\n\n* Scheduled for elective percutaneous transhepatic biliary drainage (PTBD) and\u002For biliary stenting\n* ASA physical status II-IV\n* Fasting time of at least 6 hours prior to the procedure\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Inability to provide informed consent or to complete study assessments (e.g., Ramsay Sedation Scale, FRAIL scale, Numeric Rating Scale)\n* Clinical diagnosis of Alzheimer's Disease\n* Clinical diagnosis of demantia\n* Known allergy or hypersensitivity to propofol, remifentanil, ketamine, ondansetron, or deksketoprofen\n* Grade 3-4 aortic, mitral, or tricuspid valve disease\n* Advanced or decompensated heart failure (ejection fraction \\\u003C25%)\n* Emergency procedures\n* Refusal to participate in the study","ALL","18 Years",{"count":19,"type":20},98,"ESTIMATED","INTERVENTIONAL",[23],"NA","This prospective, randomized, single-center study aims to evaluate and compare two different sedation and analgesia regimens used during percutaneous transhepatic biliary drainage (PTBD) procedures. A total of 96 adult patients undergoing elective PTBD or biliary stenting will be randomized to receive either propofol-remifentanil or propofol-ketamine sedation. The primary outcome is recovery time assessed using the Modified Aldrete Score. Secondary outcomes include procedure quality, pain scores, patient and operator satisfaction, hemodynamic stability, and the incidence of sedation-related adverse events. The study is designed to determine the optimal sedation strategy for PTBD, particularly in fragile and elderly patient populations.",[26,27,28,29],"Fragility","Biliary Obstruction","Cholangitis","Malignancy",[31,32,33,34,35],"FRAGILITY","Percutaneous Transhepatic Biliary Drainage","SEDATION","KETAMINE","REMİFENTANIL","RECRUITING","2026-06-08",{"date":39,"type":40},"2026-06-10","ACTUAL",{"date":42,"type":40},"2026-02-01",{"date":39,"type":20},{"name":45,"class":46},"Ankara City Hospital Bilkent","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":47},"100510351","preventive-effect-of-prophylactic-oral-antibiotics-against-cholangitis-after-kasai-portoenterostomy-100510351","NCT05925309","Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy","Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy in Biliary Atresia: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients whose age of operation is 14-90 d. Sex and race are not restricted;\n* Patients who are born with gestational age older than 36 weeks;\n* Patients whose body weight before operation \\> 2 kg;\n* Patients diagnosed of type-III BA and underwent KP in Children's Hospital of Fudan University;\n* The type-III BA diagnosis is based on cholangiography or operation;\n* Patients whose histological features of liver biopsies are reported. HE staining and Masson staining are required, and edema, inflammation, fibrosis, and hyperplasia of intrahepatic bile duct should be reported;\n* Patients who are not allergic to postoperative medications;\n* Patients who haven't accepted other antibiotic or probiotic therapy.\n\nExclusion Criteria:\n\n* Patients with cholestasis of non-BA disease;\n* Patients who have undergone KP at other institutions;\n* Patients whose pathohistological diagnosis is in doubt;\n* Patients who undergo liver transplantation immediately after KP;\n* Patients with other liver diseases or severe complications (e.g., severe pulmonary hypertension, renal failure, intracranial hemorrhage, etc.) requiring surgical intervention or other medical therapy;\n* Patients with severe cardiac, renal, or central nerve system malformations (e.g., tetralogy of Fallot, transposition of the great arteries, cerebral dysplasia, etc.) and have poor prognosis;\n* Patients judged by the researchers that they can not comply with the study requirements.","14 Days","90 Days",{"count":58,"type":20},356,[23],"This study is non-inferiority trial design. This study aimed to investigate the effect of prophylactic oral antibiotics on preventing cholangitis in biliary atresia (BA) patients after Kasai portoenterostomy (KP) by comparing the cholangitis rate in BA patients who received prophylactic oral antibiotics and those who did not. The patients were followed up for 2 years after KP.",[62,28,63],"Biliary Atresia","Anti-Bacterial Agents","2026-05-12",{"date":66,"type":40},"2026-05-15",{"date":68,"type":40},"2023-07-01",{"date":70,"type":20},"2029-12-31",{"name":72,"class":46},"Children's Hospital of Fudan University",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100293799","effect-of-37-non-ionic-contrast-agent-during-ercp-procedure-in-hilar-cholangiocarcinoma-100293799","NCT03104569","Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma","Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma: A Prospective Double-blind Multicenter Randomized Controlled Study","Inclusion Criteria:\n\n* Type Ⅰ、Ⅱ、Ⅲ、Ⅳ of Hilar Cholangiocarcinoma;\n* Age: 18\\~90 years old;\n* Underwent diagnostic and therapeutic ERCP;\n\nExclusion Criteria:\n\n* Coagulation dysfunction(INR\\>1.3) or\u002Fand low peripheral blood platelet count （PLT \\\u003C50x10\\^9\u002FL）;\n* Preoperative acute cholangitis;\n* Preoperative acute pancreatitis;\n* Preoperative hemobilia or hemorrhage of digestive tract;\n* Preoperative liver failure;\n* Combined with Mirizzi syndrome and intrahepatic bile duct stones;\n* Preoperative malignant tumor of biliary system such as carcinoma of head of pancreas, gallbladder carcinoma;\n* Biliary-duodenal fistula confirmed during ERCP;\n* A history of reconstructive surgery for upper digestive tract except Billroth Ⅰand a history of cholangioenterostomy including cholangio-jejunostomy and side to side anastomosis of the bile duct and duodenum;\n* Previous ERCP;\n* Pregnant women","90 Years",{"count":82,"type":20},100,[23],"The purpose of this study is to determine the effect of normal temperature and 37℃ non-ionic contrast agent acting on ERCP-related cholangeitis after endoscopic retrograde cholangiopancreatography (ERCP) in the treatment of hilar cholangiocarcinoma.",[28],[87,88,89,28,90],"ERCP","Contrast agent","Hilar cholangiocarcinoma","Nonionic","NOT_YET_RECRUITING","2025-12-19",{"date":94,"type":40},"2025-12-26",{"date":96,"type":20},"2026-04-01",{"date":98,"type":20},"2028-12-01",{"name":100,"class":46},"Hepatopancreatobiliary Surgery Institute of Gansu Province",3,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":110,"enrollmentInfo":111,"targetDuration":113,"studyType":114,"phases":4,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":47},"100602910","cholangitis-definition-and-treatment-after-kasai-hepatoportoenterostomy-for-biliary-atresia-track-ba-study-tracking-cholangitis-post-kasai-in-biliary-atresia-100602910","NCT07129655","Cholangitis Definition and Treatment After Kasai Hepatoportoenterostomy for Biliary Atresia: TRACK-BA Study (TRacking Cholangitis Post Kasai in Biliary Atresia)","Cholangitis Definition and Treatment After Kasai Hepatoportoenterostomy for Biliary Atresia: a Feasibility Study","TRACK-BA","Inclusion Criteria:\n\n* patients with a suspected diagnosis cholangitis within 1 year after Kasai hepatoportoenterostomy\n\nExclusion Criteria:\n\n* recurrent cholangitis, cholangitis \\>1 year after Kasai","2 Years",{"count":112,"type":20},40,"1 Year","OBSERVATIONAL","Biliary atresia is a rare liver disease affecting newborns. In those babies bile ducts are blocked, and bile cannot flow from the liver to the intestines. Biliary atresia patients require a special surgery called \"Kasai operation\" to restore the bile flow. A common and serious problem after surgery is an infection of the bile ducts, called cholangitis, which can damage the liver and lead an earlier need for liver transplantation.\n\nIn 2022, a group of international experts led by the Swiss Pediatric Liver Center from the HUG created new guidelines to help identify and treat cholangitis more consistently.\n\nThis study will test how well these new definitions work in real life of hospitals. Over one year, physicians will collect data on children in whom they suspect cholangitis in the first year after their Kasai. The goal is to see whether these new definitions are applicable in the clinical setting.\n\nThe study will involve around 40 patients and will use secure methods to store data. The findings will help improve how cholangitis is diagnosed and treated, making care more effective and consistent for children with biliary atresia.",[117,28],"Biliary Atresia, Kasai Portoenterostomy Status",[119,120,121],"biliary atresia","Kasai hepatoportoenterostomy","acute cholangitis","2025-08-11",{"date":124,"type":40},"2025-08-19",{"date":126,"type":20},"2025-10-01",{"date":128,"type":20},"2026-09-30",{"name":130,"class":46},"University Hospital, Geneva",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":21,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100443997","quick-large-balloon-dilatation-for-removal-of-large-bile-duct-stones-shodbadi-100443997","NCT05061680","Quick Large Balloon Dilatation for Removal of Large Bile Duct Stones (SHODBADI)","Endoscopic Papillary Short Duration Large Balloon Dilatation for Removal of Large Bile Duct Stones: a Prospective Multicenter Study of Short and Long-term Adverse Events","SHODBADI","Inclusion Criteria:\n\n* Age \\>18 years\n* Common bile duct stone \\>10mm diameter\n\nExclusion Criteria:\n\n* Altered anatomy after surgery (B II, Roux-en-Y reconstruction)\n* Common bile duct cysts\n* Acute pancreatitis\n* Distal common bile duct stricture or tumor\n* Coagulation disorders\n* Ongoing coagulation medication\n* Pregnancy\n* Inability to give an informed consent","95 Years",{"count":141,"type":20},600,[23],"ESGE guidelines suggests 30-60 seconds endoscopic large balloon papillary dilation from the disappearance of the waist of the papilla.\n\nThe investigators have good results in stone removal with much quicker dilatations when the cholangiogram is followed and the dilation is finished as soon as the disappearance of the waist of the papilla is seen. This Scandinavian multicenter prospective study is especially interested in stone clearance rate and short and long-term adverse events such as pancreatitis, cholangitis, bleeding, perforations, residual biliary stones, and newly developing biliary stones.",[145,146,28],"Pancreatitis, Acute","Bleeding","2023-02-28",{"date":149,"type":40},"2023-03-01",{"date":151,"type":40},"2021-04-05",{"date":153,"type":20},"2026-12-31",{"name":155,"class":46},"Helsinki University Central Hospital",2]